US FDA approves Amgen’s Uplizna as first treatment for rare immune disorder
By Deena Beasley, Mariam Sunny and Siddhi Mahatole (Reuters) -The U.S. Food and Drug Administration has approved expanded use of Amgen’s drug, Uplizna, to help reduce the risk of flares in patients with a rare immune system-related condition, the regulator said on Thursday. The drug, also known as inebilizumab, has now become the first FDA-approved…
